Lupin Ltd Drug Patent Portfolio

Lupin Ltd owns 1 orange book drug protected by 1 US patent Given below is the list of Lupin Ltd's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9233112 Pharmaceutical compositions of cefixime 14 Dec, 2028
Active


Lupin Ltd's Family Patents

Lupin Ltd drugs have patent protection in a total of 3 countries. It's US patent count contributes only to 50.0% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Recently granted tentative Approvals to Lupin Ltd

These tentative approvals reflect continued regulatory progress across both innovative and generic submissions related to Lupin Ltd's portfolio.

Innovator tentative approvals

Drug Name Active Ingredient Submission Type Submission Category Submission Date
Dolutegravir;lamivudine;tenofovir Alafenamide Dolutegravir;lamivudine;tenofovir Alafenamide ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 4 - New Combination 18 Jul, 2023
Dolutegravir; Emtricitabine; Tenofovir Alafenamide Dolutegravir;emtricitabine;tenofovir Alafenamide ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 4 - New Combination 19 Jan, 2023
Dolutegravir, Lamivudine And Tenofovir Disoproxil Fumarate Dolutegravir; Lamivudine; Tenofovir Disoproxil Fumarate ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 4 - New Combination 25 Jun, 2021

Generic tentative approvals

Drug Name Active Ingredient Submission Type Submission Category Submission Date
Armodafinil Armodafinil ORIG-2
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Not Applicable 28 Nov, 2016
Doxycycline Doxycycline ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
(Not Available) 29 Jul, 2013
Irbesartan And Hydrochlorothiazide Hydrochlorothiazide; Irbesartan ORIG-2
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Not Applicable 27 Feb, 2013

Explore deeper patents analysis

Lupin Ltd Drug List

Given below is the complete list of Lupin Ltd's drugs and the patents protecting them.


1. Suprax

Suprax is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9233112 Pharmaceutical compositions of cefixime 14 Dec, 2028
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Suprax's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Lupin Ltd News

Upcoming expirations of GLP-1 drug patents attract generic manufacturers - C&EN

09 Dec, 2025

NCLAT rules that CCI is unable to investigate anti-competitive behavior related to patented medications - Bar and Bench

31 Oct, 2025

Boost for Indian pharmaceutical companies as US FDA relaxes regulations on biosimilar approvals.

31 Oct, 2025

ANDA Litigation Settlements for Q3 2025 | Robins Kaplan LLP - JDSupra

30 Oct, 2025

See More